Literatura académica sobre el tema "B]thiazole"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "B]thiazole".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "B]thiazole":
Mohareb, Rafat M., Amira E. M. Abdallah y Ebtsam A. Ahmed. "Synthesis and cytotoxicity evaluation of thiazole derivatives obtained from 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene- 3-carbonitrile". Acta Pharmaceutica 67, n.º 4 (20 de diciembre de 2017): 495–510. http://dx.doi.org/10.1515/acph-2017-0040.
Andreani, Aldo, Mirella Rambaldi y Alessandra Locatelli. "Herbicidal activity of 5-haloimidazo[2,1-b]thiazoles". Collection of Czechoslovak Chemical Communications 56, n.º 11 (1991): 2430–35. http://dx.doi.org/10.1135/cccc19912430.
Molina, Pedro, Antonio Arques, Maria de los Desamparados Velasco y Jos� Manuel Villalgordo. "Fused Thiazoles from 3-Amino-thiazoline-2-thiones: Synthesis of Pyrazolo[5,1-b]thiazole and Thiazolo[2,3-b]-1,3,4-thiadiazine Derivatives". HETEROCYCLES 26, n.º 5 (1987): 1323. http://dx.doi.org/10.3987/r-1987-05-1323.
Jaberi, Hamid Reza y Hadi Noorizadeh. "Synthesis of Some Novel Fused Imidazo [2, 1-b] [1, 3] Thiazole and Imidazo [2, 1-b] Thiazolo [5, 4-d] Isoxazole Derivatives". E-Journal of Chemistry 9, n.º 3 (2012): 1518–25. http://dx.doi.org/10.1155/2012/896454.
Lan, Zheng y Wang. "2-(3,5-Dimethyl-1H-pyrazol-1-yl)thiazolo[4,5-b]pyridine". Molbank 2019, n.º 3 (20 de agosto de 2019): M1077. http://dx.doi.org/10.3390/m1077.
Özbey, Süheyla y Asiye Meriç. "3,4-Di-p-tolyl-6,7-dihydroimidazo[2,1-b][1,3]thiazole". Acta Crystallographica Section E Structure Reports Online 62, n.º 7 (14 de junio de 2006): o2717—o2719. http://dx.doi.org/10.1107/s160053680602099x.
El-Hagrassey, Eman A., Ehab Abdel-Latif y Gamal M. Abdel-Fattah. "Synthesis and efficiency of new pyridine, chromene and thiazole containing compounds as antimicrobial and antioxidant agents". Bulletin of the Chemical Society of Ethiopia 36, n.º 1 (28 de marzo de 2022): 137–48. http://dx.doi.org/10.4314/bcse.v36i1.12.
Shaik, Siddiq P., Telukutta S. Reddy, Satish Sunkari, Ayinampudi V. S. Rao, Korrapati S. Babu, Suresh K. Bhargava y Ahmed Kamal. "Synthesis of Benzo[d]imidazo[2,1-b]thiazole-Propenone Conjugates as Cytotoxic and Apoptotic Inducing Agents". Anti-Cancer Agents in Medicinal Chemistry 19, n.º 3 (25 de junio de 2019): 347–55. http://dx.doi.org/10.2174/1871520619666181127112621.
Lei, Jiaying, Xinliang Fu, Yulin Huang y Xiaofang Li. "Synthesis of spiro[benzo[4,5]imidazo[2,1-b][1,3]thiazole-2,3-thiolane]s via sulfa-Michael/aldol cascade reactions". Journal of Chemical Research 43, n.º 1-2 (enero de 2019): 63–66. http://dx.doi.org/10.1177/1747519819831898.
Gobala Krishnan P, Gnanaprakash K y Chandrasekhar KB. "Design, synthesis, characterization and antitubercular activity of some nov-el 2, 4-disubstituted thiazole derivatives". International Journal of Research in Pharmaceutical Sciences 10, n.º 2 (23 de abril de 2019): 1504–9. http://dx.doi.org/10.26452/ijrps.v10i2.729.
Tesis sobre el tema "B]thiazole":
Ollivierre, H. M. "The synthesis and chemistry of 1,2,3-triazolo(5,1-b)thiazole". Thesis, Keele University, 1990. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.293924.
Boukraa, Sadok. "Préparation, réactivité et étude des propriétés fongistatiques et immunostimulantes d'amino-2 thiazoles et d'imidazo-(2,1-B) thiazoles". Besançon, 1987. http://www.theses.fr/1987BESA2030.
Le, Meur Mikaël. "Identification de nouveaux inhibiteurs de l’agrégation de la protéine Tau". Thesis, Orléans, 2014. http://www.theses.fr/2014ORLE2046.
TAU pathology is a brain lesion common to more than twenty neurodegeneratives diseases. It consists of the abnormal aggregation of the microtubule-associated protein TAU into neurofibrillary tangles. While mechanisms underlying TAU aggregation are not fully understood yet, we have been investigated the synthesis and the biological evaluations of novel class of TAU aggregation inhibitors involved in Alzheimer’s disease. The first two parts of this work reports the synthesis of various imidazo[2,1-b]thiazoles molecules, on which are substituted (het)aryles groups. The third and last part is devoted to the formation of some di-/trisubstituted novel N-fused ring system such as thiazolo[3,2-b]triazoles. In order to provide a functional diversity and generate a therapeutic effect, the peaks C-2, C-3, C-5 and C-6 were functionalized on the imidazo[2,1-b]thiazole ring. It was also the opportunity to develop news synthetic methodologies such as a new Suzuki-Miyaura reaction, a multicomponent reaction, and an electrophilic condensation. On the thiazolotriazole core, an effective procedure of CH activation was performed. More than two hundred original molecules were synthesized, and more than half were evaluated in vitro. A fluorescence technique allowed us to determine the inhibition of TAU aggregation, using the particular K18 protein as a truncated model of normal TAU protein
MADADI, MESSAOUD NACER. "Recherche en pharmacochimie heterocyclique antiparasitaire : pharmacomodulation de derives thiopheniques et reactions de transfert monoelectronique en serie imadazo (1,2-a) pyridine et en serie imadazo (2,1-b) thiazole". Aix-Marseille 2, 1991. http://www.theses.fr/1991AIX22956.
Juspin, Thierry. "Synthèse et fonctionnalisation d'hétérocycles d'intérêt biologique par méthologie TDAE". Thesis, Aix-Marseille 2, 2010. http://www.theses.fr/2010AIX22950/document.
This work is focused on the synthesis and the functionalization of potentially bioactive heterocyclic compounds by TDAE methodology. In the first part, we have developed the TDAE reaction with new electrophiles in nitrobenzylic series. By using ethylenic and heterocyclic aldehydes, we have identified the kind of nucleophilic addition (classic or Michael). The reaction on a carbon-nitrogen double bond is possible with the utilization of quaternary iminiums. We have presented the first example of double TDAE-initiated reactivity with aromatic dialdehydes. A short and original methodology allows us to synthesize quinolines in a two steps TDAE-initiated reaction (using diketones as electrophiles) and reduction-cyclization reaction. In the second part, we have applied the TDAE methodology in order to discover pharmacological compounds. After synthesizing the 6-chloromethyl-5-nitroimidazo[2,1-b]thiazole, we have studied its reactivity with different a-ketoesters. All the products were tested as antibacterial and antifungal compounds; they show a specific activity against Candida tropicalis. In the third part, we synthesized the 4-[4-(chloromethyl)phenyl]-1,2-dimethyl-5-nitro-1H-imidazole. The TDAE-initiated reactivity of this substrate with different electrophiles (aldehydes, a-ketoesters, diketones) furnish new potentially bioactive alcohols as antiparasitic agents especially against Trichomonas vaginalis
Boukraa, Sadok. "Préparation, réactivité et étude des propriétés fongistatiques et immunostimulantes d'amino-2 thiazoles et d'imidazo-(2,1-b) thiazoles". Grenoble 2 : ANRT, 1987. http://catalogue.bnf.fr/ark:/12148/cb376032986.
Ejjoummany, Abdelaziz. "Design et fonctionnalisation d’hétérocycles originaux de type bicycliques [5-5] et tricycliques [6-5-6] à visée thérapeutique potentielle". Thesis, Orléans, 2020. http://www.theses.fr/2020ORLE3141.
The access to new original biologically active heterocyclic compounds, is one of the main objectives of our research group. In this context, the main purpose of this thesis is the design of three new families of heterocyclic compounds containing a pyrazolic motif that may exhibit biological activities, namely pyrido[1',2': 1.5]pyrazolo[4,3-d]pyrimidine, pyrrolo[3,4-c]pyrazole and pyrazolo[5,1-b]thiazole.This manuscript is essentially dedicated to a methodology work describing the different routes of access to these originals and potentially modular tricyclic and bicyclic precursors. The reactivity of these key synthons is then studied towards aromatic nucleophilic substitutions reactions and various pallado-catalyzed methods of functionalization (Activation with PyBrOP- (hetero) arylation, Liebeskind-Srogl, Suzuki-Miyaura, Buchwald-Hartwig, C-H arylation, aromatic nucleophilic substitution) to develop interesting libraries built around these unusual structures, thus opening numerous pharmacological perspectives
Chew, Angela Christine. "The anti-proliferative effects of thiazolidinediones and non-steriodal anti-inflammatory drugs on androgen-independent prostate cancer". University of Western Australia. School of Medicine and Pharmacology, 2009. http://theses.library.uwa.edu.au/adt-WU2009.0200.
Kalyon, Bahar [Verfasser], Roderich [Akademischer Betreuer] SüßMuth y Hans-Peter [Akademischer Betreuer] Fiedler. "Fermentation, Isolierung und Strukturaufklärung der ribosomal synthetisierten Thiazol/Oxazol-Peptide Plantazolicin A und B aus Bacillus amyloliquefaciens FZB42 und Strukturaufklärung der Langkocycline aus Streptomyces sp. Acta 3034 / Bahar Kalyon. Gutachter: Roderich Süßmuth ; Hans-Peter Fiedler". Berlin : Technische Universität Berlin, 2014. http://d-nb.info/1067384782/34.
Almeida, Mário Rui Dias. "Synthesis of 5-aryl-imidazo [2,1-b] thiazole compounds possibly RAF kinase inhibitors". Master's thesis, 2014. http://hdl.handle.net/10451/38753.
Malignant melanoma is the most aggressive type of skin cancer because of its high tendency to metastasize. In fact, the mortality rate from malignant melanoma has risen about 2% annually since 1960. Malignant melanoma occupies the 19th place as the most common cancer worldwide. In Portugal, according to the Portuguese League Against Cancer are nearly 700 new cases of melanoma annually and the incidence rate reaches 6-8 cases per 100000 individuals. These data are similar to South European countries, namely, Spain and Italy. There are several options of treatments for malignant melanoma and the right choice depends of several aspects, being the most important one, the actual stage of the cancer. The understanding of carcinogenesis’ mechanisms at the molecular level has led to the opportunity of development new therapeutic approaches. Recently, some pyrimidinyl substituted imidazo[2,1-b]thiazole derivatives were reported as RAF kinases inhibitors. Therefore, these compounds provide a broad and novel opportunity to treat melanoma, which should be further investigated. The obtained compounds, showing promising proprieties, will be further investigated to evaluate its pharmacokinetic and toxicokinetic proprieties in biological assays performed in several melanoma cultured cells.
O melanoma maligno é o tipo de cancro de pele mais grave devido à sua alta tendência para metastizar. Desde 1960, a sua taxa de mortalidade tem aumentado cerca de 2% anualmente. O melanoma maligno ocupa o 19º lugar entre os cancros mais comuns a nível mundial. Em Portugal, de acordo com a Liga Portuguesa Contra o Cancro existem cerca de 700 novos casos de melanoma por ano e a taxa de incidência de melanoma é de 6-8 casos por 100000 pessoas, bastante similar aos países do Sul da Europa, nomeadamente Espanha e Itália. Existem várias opções terapêuticas para o melanoma maligno, no entanto, a escolha mais adequada depende de vários fatores, sendo o mais importante, o estadio do cancro. A compreensão dos mecanismos de carcinogénese, numa perspetiva molecular, permitiu o desenvolvimento de novas opções terapêuticas. Recentemente, alguns derivados imidazo[2,1-b]tiazólicos com grupos pirimidínicos substituídos foram descritos como inibidores das quinases RAF. Consequentemente, estes compostos permitem uma inovadora modalidade de tratamento do melanoma que deve ser explorada. Os compostos sintetizados neste trabalho, caso sejam realmente promissores, serão investigados mais aprofundadamente, para avaliar as suas propriedades farmacocinéticas e toxicodinâmicas em ensaios biológicos realizados em diversas linhas celulares de melanoma.
Capítulos de libros sobre el tema "B]thiazole":
Forti, G. Cantelli, P. Hrelia, M. C. Guerra, M. Paolini, A. M. Barbaro y G. L. Biagi. "Genotoxic Activity of Nitroimidazo(2,1-b)Thiazole Derivatives in Salmonella Typhimurium and Saccharomyces Cerevisiae Assays". En Archives of Toxicology, 408. Berlin, Heidelberg: Springer Berlin Heidelberg, 1985. http://dx.doi.org/10.1007/978-3-642-69928-3_89.
Hegde, Shridhar G., Martin D. Mahoney y Claude R. Jones. "Thiazolo[4,5-b]pyridine-3(2H)-acetic Acid Derivatives". En ACS Symposium Series, 70–77. Washington, DC: American Chemical Society, 1995. http://dx.doi.org/10.1021/bk-1995-0584.ch007.
Biagi, G. L., P. Hrelia, M. C. Guerra, M. Paolini, A. M. Barbaro y G. Cantelli-Forti. "Structure-Activity Relationshipof Nitroimidazo (2,1-b) Thiazoles in the Salmonella Mutagenicity Assay". En Archives of Toxicology, 425–29. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-71248-7_86.
"2,3-Dihydro-7H-pyrido[2,1-b]-1,3-thiazole". En Substance Index, editado por Backes, Fröhlich y Padeken. Stuttgart: Georg Thieme Verlag, 2000. http://dx.doi.org/10.1055/b-0035-114034.
"1,3-Thiazole(I)". En Substance Index, editado por Backes, Fröhlich y Pedeken. Stuttgart: Georg Thieme Verlag, 1999. http://dx.doi.org/10.1055/b-0035-114060.
"1,3-Thiazole(II)". En Substance Index, editado por Backes, Fröhlich y Pedeken. Stuttgart: Georg Thieme Verlag, 1999. http://dx.doi.org/10.1055/b-0035-114061.
"Tetrahydro-1,3-thiazole, 1,3-Thiazolidine to 4,5-Dihydro-1,3-thiazolium". En Substance Index, editado por Backes, Fröhlich y Pedeken. Stuttgart: Georg Thieme Verlag, 1999. http://dx.doi.org/10.1055/b-0035-114059.
Sammakia, Tarek, Eric L. Stangeland y Mark C. Whitcomb. "Chapter 13 Functionalization of pyridines and thiazoles via the halogen-dance reaction, application to the total synthesis of caerulomycin c and WS75624 B". En Strategies and Tactics in Organic Synthesis, 415–36. Elsevier, 2005. http://dx.doi.org/10.1016/s1874-6004(05)80036-x.
Actas de conferencias sobre el tema "B]thiazole":
Nikhila, G. R., S. R. Batakurki y B. C. Yallur. "Synthesis, characterization and antioxidant studies of benzo[4, 5]imidazo[2, 1-b]thiazole derivatives". En PROCEEDINGS OF INTERNATIONAL CONFERENCE ON ADVANCES IN MATERIALS RESEARCH (ICAMR - 2019). AIP Publishing, 2020. http://dx.doi.org/10.1063/5.0023101.
Al-Jamal, Mazin H., Naeemah Al-Lami y Ruqia M. Al-Azy. "Synthesis of new S, N, O-alkylated benzo [d] imidazo [2,1-b]thiazole and the study of their biological applications". En 2ND INTERNATIONAL CONFERENCE ON MATERIALS ENGINEERING & SCIENCE (IConMEAS 2019). AIP Publishing, 2020. http://dx.doi.org/10.1063/5.0000174.
Fidanze, Steve D., Scott A. Erickson, Robert D. Hubbard, Gary T. Wang, Robert A. Mantei, Nwe Y. BaMaung, Richard F. Clark et al. "Abstract A245: Imidazo[2,1‐b]thiazole and imidazo[1,2‐a]pyridine amides as novel inhibitors of the insulin‐like growth factor (IGF1R) and members of the epidermal growth factor family of tyrosine kinases". En Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/1535-7163.targ-09-a245.